FIG. 1: Hair-transplantation - Harvesting with the follicular unit excision method (FUE) for HAIROID™️ replication at  “patient zero”.

FIG. 2: In HAIROID ™️ it is possible to observe the dermal papilla, hair matrix, outer and inner root sheath and hair shaft [hematoxylin eosin staining].

Our first focus is to produce, autologous and allogeneic, hypoimmunogenic GENE EDITED hair-follicles for ALOPECIA treatments supplied in our clinics and the transplantation into the human scalp.

With its patented high-tech 3D stem-cell merger technology, HAIROID ™️, which is a spin-off from an EUROPEAN CONTRACT RESEARCH ORGANISATION, performs its own organoid development that is equivalent to pharmaceutical and cosmetics companies. This is done in the discovery and preclinical testing phase in order to increase efficiency and the success rate of compounds/organoids that pass the clinical trials.

Here we focus on ALOPECIA diseases, the performance  of highly sophisticated tissue (hair)-engineering and in silico computerial screening technologies.

Prior to the transplantation of bioengineered hair-follicles we will provide to physicians and professionals cell viability/proliferation assays, DERMAL PAPILLAE isolation, HAIR BULGE STEM CELL isolation, IPSC reprogramming, tissue engineering and cryogenic storage.

For developers of STEM-CELL THERAPIES we will provide our IP protected  hypoimmunogenic Dermal Papillae Cells in order to contribute to the development of STEM-CELL THERAPIES FOR ALOPECIA. OUR METHODS CAN BE APPLIED TO ALREADY PRODUCED CELL LINES.

IN Q4 2021 WE WILL INTRODUCE OUR BIOENGINEERED ADIPOCYTES FOR WOUNDHEALING, COSMETIC SURGERY AND RECONSTRUCTION SURGERY TO SELECTED CLINICIANS.

Image 3.: HAIROID™️ prototype April 2018